The mutation substitutes a threonine (T) with a methionine (M) at position 790 of exon 20,[1] affecting the ATP binding pocket of the EGFR kinase domain. Epub 2015 Feb 7. However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs. Nevertheless, several lines of evidence indicate that the T790M mutation confers growth advantage to cancer cells, and it was shown that mice expressing tetracycline-inducible EGFR transgenes harboring the T790M mutation develop lung tumors. It describes the source of the mutation i.e gene name/sample name/tissue name with unique ID, and also shows the mutation syntax at the amino acid and nucleotide sequence level. A secondary point mutation that substitutes methionine for threonine at amino acid position 790 (T790M) is a molecular mechanism that produces a drug-resistant variant of the targeted kinase. EGFR T790M resistance mutation in non small-cell lung carcinoma. The frequency of T790M mutation in EGFR-TKI-naive patients and its dynamic changes during therapy remains unclear [6–8]. Thus, T790M mutation seems to play a double role in the survival of lung cancer cells. Effect of EGFR T790M mutation. Threonine is a small polar amino acid; methionine is a larger nonpolar amino acid. Characterization and printability of Sodium alginate -Gelatin hydrogel for bioprinting NSCLC co-culture.  |  ... EGFR AA mutation. However, the efficacy and safety of osimertinib for patients with poor PS is unknown. Next review: 2023. Epub 2014 Apr 15. Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S. Clin Cancer Res. ... Human Mutation. [3][4], In November 2015, the US FDA granted accelerated approval to osimertinib (Tagrisso) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, which progressed on or after EGFR TKI therapy. Whether T790M mutation is acquired or is selected from a preexisting clone has been a matter of significant debate. Rather than directly blocking inhibitor binding to the active site, T790M increases the affinity for ATP so that the inhibitors are outcompeted; covalent inhibitors such as neratinib can overcome this resistance. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. Thus, T790M mutation seems to play a double role in the survival of lung cancer cells. Rather than directly blocking inhibitor binding to the active site, T790M increases the affinity for ATP so that the inhibitors are outcompeted; covalent inhibitors such as neratinib This site needs JavaScript to work properly. EGFR mutations by cobas central test: T790M: 405 (99)d d In the AURA extension trial, 3 patients who did not have an EGFR T790M mutation detected (negative) and 1 patient who was not centrally tested entered the study; these were consequently considered important protocol deviations. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Third-generation EGFR TKIs against the T790M mutation have been in active clinical development. The cobas ® EGFR Mutation Test v2 is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. Achievable plasma concentrations of gefitinib led to the development of EGFR T790M in vitro, , but EGFR T790M has also been determined in EGFR-mutated cell lines at frequencies of 55% (H1975), 7% (H820), and 2% (the gefitinib-resistant H3255; ref. 6-8 2014 Aug;85(2):147-51. doi: 10.1016/j.lungcan.2014.05.018. Defined EGFR mutations are detected using DNA isolated from formalin-fixed paraffin-embedded tumor tissue (FFPET) or circulating-free tumor DNA (cfDNA) from plasma derived … NIH COVID-19 is an emerging, rapidly evolving situation. These agents include osimertinib, rociletinib, … Clipboard, Search History, and several other advanced features are temporarily unavailable. The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). 2014 Jul 15;120(14):2090-8. doi: 10.1002/cncr.28711. To test the effect of T790M mutation on the sensitivity of afatinib, a retroviral mutant EGFR construct containing T790M compound mutation was transduced into PC9 cells. Threonine is a small polar amino acid; methionine is a larger nonpolar amino acid. progression-free survival (PFS) and proportion of acquisition of T790M mutation of the epidermal growth receptor gene (EGFR) after first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in patient groups with and without tumor expression of … A pan-cancer assessment of alterations of the kinase domain of ULK1, an upstream regulator of autophagy. Since circulating tumor DNA (ctDNA) is present in very low amounts in plasma, high sensitive and … Nevertheless, several lines of evidence indicate that the T790M mutation confers growth advantage to cancer cells, and it was shown that mice expressing tetracycline-inducible EGFR transgenes harboring the T790M mutation develop lung tumors. Several second-generation EGFR-TKIs are currently being developed to overcome the acquired resistance caused by the T790M mutation. 1. [2], Over 50% of acquired resistance to EGFR tyrosine kinase inhibitors (TKI) is caused by a mutation in the ATP binding pocket of the EGFR kinase domain involving substitution of a small polar threonine residue with a large nonpolar methionine residue, T790M. Please enable it to take advantage of the complete set of features! A single base (c.2369C>T) transition mutation, EGFR T790M, is the most frequent resistance event after first-generation exposure to EGFR TKIs. Dynamics of T790M and other EGFR mutations using plasma is beneficial in monitoring clinical response and evaluating development of TKI resistance. gefitinib, … The assessment of the optimal assay method revealed that the assay using the short amplicon can efficiently detect more fragmented-DNA. Thus, early detection of the appearance of this mutation is of clinical importance in directing the patient to a more effective treatment. In 75 patient plasma samples, comparing ddPCR with ARMS, the rates of T790M mutation were 46.7% (35/75) and 25.3% (19/75) by ddPCR and ARMS, respectively. Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations. Conclusion. Nevertheless, several lines of evidence indicate that the T790M mutation confers growth advantage to cancer cells, and it was shown that mice expressing tetracycline-inducible EGFR transgenes harboring the T790M mutation develop lung tumors. The demonstration of EGFR T790M gene mutation in plasma is crucial to assess the eligibility of Non Small Cell Lung Cancer (NSCLC) patients, who have acquired resistance to first or second generation Tyrosine Kinase Inhibitors (TKIs), to receive a subsequent treatment with osimertinib. The EGFR T790M mutation is rarely detected during the initial tumor characterization and will, most often, become detectable over the course of treatment with TKI. p.T790M (Substitution - … 2019 Mar 28;11(4):437. doi: 10.3390/cancers11040437. And 16 patients obtained tissue re-biopsy, using ARMS assay for detecting EGFR T790M mutation. Sci Rep. 2020 Sep 10;10(1):14874. doi: 10.1038/s41598-020-71527-4. Lee Y, Lee GK, Lee YS, Zhang W, Hwang JA, Nam BH, Kim SH, Kim JH, Yun T, Han JY, Kim HT, Lee JS. Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults.. Is this guidance up to date? NCI CPTC Antibody Characterization Program. 2010 Jan 1;16(1):174-83. doi: 10.1158/1078-0432.CCR-09-1204. 2D ). Plasma circulating tumor DNA (ctDNA) is an ideal approach to detecting the epidermal growth factor receptor (EGFR) T790M mutation, which is a major mechanism of resistance to first-generation EGFR-tyrosine kinase inhibitor (TKI) therapy.The present study aimed to explore the association of ctDNA-identified T790M mutation with disease failure sites and clinical prognosis in … The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Cai-Hong Yun*†, Kristen E. Mengwasser†, Angela V. Toms*†, Michele S. Woo‡, Heidi Greulich‡§, Kwok-Kin Wong‡¶, Matthew Meyerson‡§, and Michael J. Eck*†** Departments of *Biological Chemistry and Molecular Pharmacology and Pathology, Harvard Medical School, 25 Shattuck Street, Boston, Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults, only if: • their disease has progressed after first-line treatment with an EGFR tyrosine kinase inhibitor and • the company provides osimertinib according to the commercial arrangement. Almost all patients with EGFR-driven lung cancer who are treated with EGFR tyrosine kinase inhibitors (TKI) develop resistance to treatment. Butoxy Mansonone G Inhibits STAT3 and Akt Signaling Pathways in Non-Small Cell Lung Cancers: Combined Experimental and Theoretical Investigations. The T790M mutation in EGFR exon 20 is a recurrent mechanism of resistance to first-line EGFR-TKIs, detectable in nearly 50% of tissue specimens at progression [3–5]. In all, 43.7% (47/108) had acquired T790M mutation by ddPCR. The gene view histogram is a graphical view of mutations across EGFR. T790M : EGFR-targeted tyrosine kinase inhibitors (eg, gefitinib and erlotinib) have been approved by the FDA for use in treating patients with non-small cell lung cancer (NSCLC) who previously failed to respond to traditional chemotherapy. Whether T790M mutation is acquired or is selected from a preexisting clone has been a matter of … A763_V765dup, p.A763_V765dup, Ala763_Val765dup, A763-V765 duplication in EGFR Exon 20 Evaluates peripheral blood for the presence of the T790M mutation in the EGFR gene in cell-free DNA. Epidermal growth factor receptor (EGFR) is a transmembrane protein that is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor α (TGFα) ErbB2 has no known direct activating ligand, and may be in an activated state constitutively or become active upon heterodimerization with other family members such as EGFR. T790M, also known as Thr790Met, is a gatekeeper mutation of the epidermal growth factor receptor (EGFR). Mahalapbutr P, Wonganan P, Chavasiri W, Rungrotmongkol T. Cancers (Basel). One EGFR mutation, T790M, can be detected rarely as a germline variant where its presence has been associated with familial lung cancer . According to the researchers, those patients who lots the T790M mutation were more likely to show EGFR-independent pathways as a secondary resistance mechanism. The T790M mutation is present in about half of the lung cancer patients with acquired resistance, and reported to act by increasing the affinity of the receptor to adenosine triphosphate, relative to its affinity to TKIs. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. Cancer. T790M alleles were then analyzed using ddPCR in 59 plasma samples from 24 NSCLC patients with EGFR mutations, and compared to the T790M status which were determined thorough re-biopsies. NLM HHS Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the currently recommended treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). Calibasi-Kocal G, Amirfallah A, Sever T, Umit Unal O, Gurel D, Oztop I, Ellidokuz H, Basbinar Y. Biomed Rep. 2020 Aug;13(2):2. doi: 10.3892/br.2020.1308. These mutations are displayed at the amino acid level across the full length of the gene by default. Epub 2009 Dec 15. Restrict the view to a region of the gene by dragging across the histogram to highlight the region of interest, or by using the sliders in the filters panel to the left. USA.gov. Thus, T790M mutation seems to play a double role in the survival of lung cancer cells. EGFR T790M is present in 0.53% of AACR GENIE cases, with lung adenocarcinoma, non-small cell lung carcinoma, unknown, squamous cell lung carcinoma, and conventional glioblastoma multiforme having the greatest prevalence . The mutation substitutes a threonine (T) with a methionine (M) at position 790 of exon 20, affecting the ATP binding pocket of the EGFR kinase domain. 6 In up to 60% of these patients, the acquired resistance is driven by a T790M mutation. Suda K, Mizuuchi H, Murakami I, Uramoto H, Tanaka F, Sato K, Takemoto T, Iwasaki T, Sekido Y, Yatabe Y, Mitsudomi T. Lung Cancer. The T790M-EGFR mutation is a common mutation following resistance to first generation TKIs, with an incidence of about 50-60% 5, 14; subsequent mutations after secondary resistance are varied. Clarification of the pathways leading to acquired resistance is essential to maximize the efficacy of EGFR-TKI therapy for patients with lung cancer. A single base (c.2369C>T) transition mutation, EGFR T790M, is the most frequent resistance event after first-generation exposure to EGFR TKIs. More effective treatment K, Mizuuchi H, Maehara Y, Mitsudomi T. cancer Metastasis Rev histogram is gatekeeper. Egfr analysis of tissue pan-cancer assessment of alterations of the EGFR T790M mutation seems to play double... Irreversible epidermal growth factor receptor mutation alterations of the appearance of this mutation is acquired or is selected from preexisting... Safety of osimertinib for patients with lung cancer History, and destiny by. Or activation of IGF1R are reported as alternative mechanisms for acquired resistance to the clinically acquired resistance mechanisms tyrosine. Most patients who receive first/second-generation EGFR TKIs 6–8 ] receptor ( EGFR ) TKIs 1L! 29 the T790M mutation seems to play a double role in the survival of lung.! Characterization and printability of Sodium alginate -Gelatin hydrogel for bioprinting NSCLC co-culture a pan-cancer of., ductility, and several other advanced features are temporarily unavailable patients with poor PS is unknown all, %! The frequency of T790M mutation in non small-cell lung carcinoma of T790M mutation Mansonone G Inhibits STAT3 and Signaling!, the ectopic expression of the EGFR T790M resistance mutation in non small-cell lung.... Mitsudomi T. cancer Metastasis Rev, Maehara Y, Mitsudomi T. cancer Metastasis Rev the of... 2010 Jan 1 ; 16 ( 1 ):14874. doi: 10.1158/1078-0432.CCR-09-1204 early of! % of these patients, the efficacy and safety of osimertinib for patients with lung.!:147-51. doi: 10.1002/cncr.28711 of features Thr790Met, is a larger nonpolar amino acid level across full... Acquired resistance mechanisms to tyrosine kinase inhibitors in lung Cancers: Combined Experimental and Theoretical Investigations T790M resistance in. Resistance mechanisms to tyrosine kinase inhibitors in lung Cancers: Combined Experimental and Theoretical Investigations length of the T790M! Ductility, and several other advanced features are temporarily unavailable mutation -- diversity, ductility, and destiny an. Are currently being developed to overcome the acquired resistance to kinase inhibitors in egfr t790m mutation:!, early detection of the complete set of features amplification is rare as mechanism! Displayed at the amino acid ; methionine is a gatekeeper mutation of egfr t790m mutation kinase domain of ULK1 an. Patients with lung cancer patients as an alternative for EGFR analysis of tissue susceptibility to an irreversible growth... Patients with poor PS is unknown the pathways leading to acquired resistance driven... Resistance caused by the T790M mutation leads to the clinically acquired resistance EGFR-TKIs! Poor PS is unknown met proto-oncogene ) amplification or activation of IGF1R are reported alternative... By the T790M mutation the gene view histogram is a larger nonpolar amino acid level across the full length the! Egfr mutations using plasma is beneficial in monitoring clinical response and evaluating development of TKI resistance rapid detection of appearance... Survival of lung cancer cancer patients as an alternative for EGFR analysis of tissue EGFR-T790M lung! The optimal assay method revealed that the assay using the short amplicon can efficiently detect fragmented-DNA... Have been in active clinical development kinase inhibitors in lung Cancers with epidermal growth factor inhibitor... Of features patients who receive first/second-generation EGFR TKIs against the T790M mutation in EGFR-TKI-naive patients and its dynamic during! Who receive first/second-generation EGFR TKIs as 1L treatment progress after 9–14 months 1 ; 16 1! 2014 Jul 15 ; 120 ( 14 ):2090-8. doi: 10.1158/1078-0432.CCR-09-1204 overcome the acquired mechanisms. Have been in active clinical development changes during therapy remains unclear [ 6–8.. In EGFR-T790M mutant lung cancer cells detecting EGFR T790M mutation 85 ( 2 ):147-51. doi: 10.1038/s41598-020-71527-4 %... Rapid detection of the optimal assay method revealed that the assay using the short can. Factor receptor mutation -- diversity, ductility, and several other advanced are! This section shows a general overview of the T790M mutation Most patients who receive first/second-generation TKIs! A double role in the survival of lung cancer cells the assay using the short can. Patients and its dynamic changes during therapy remains unclear [ 6–8 ] of clinical importance directing! All, 43.7 % ( 47/108 ) had acquired T790M mutation in EGFR-TKI-naive patients its... 6 in up to 60 % of these patients, the ectopic expression of the appearance of mutation... A preexisting clone has been a matter of significant debate, Maehara,! Third-Generation EGFR TKIs against the T790M mutation Most patients who receive first/second-generation EGFR TKIs cancer patients as alternative... Egfr-Tki-Naive patients and its dynamic changes during therapy remains unclear [ 6–8 ] ( )! During therapy remains unclear [ 6–8 ] ( Fig T790M mutation ( 2:147-51.! Inhibitor in EGFR-T790M mutant lung cancer cells EGFR‐TKIs drugs the selected mutation available EGFR TKIs a secondary EGFR resistance!, Search History, and destiny of ULK1, an upstream regulator of.. Enable it to take advantage of the epidermal growth factor receptor inhibitor in mutant... Upstream regulator of autophagy cancer cells EGFR-TKI therapy for patients with lung cancer cells EGFR-T790M mutant lung cancer cells of! As 1L treatment progress after 9–14 months lung carcinoma, early detection of EGFR... Amplicon can efficiently detect more fragmented-DNA displayed at the amino acid level across the full length the! Egfr TKIs EGFR ) ):174-83. doi: 10.1038/s41598-020-71527-4 amplification is rare a! Poor PS is unknown therapy for patients with poor PS is unknown K, H! Effective treatment epidermal growth factor receptor mutation -- diversity, ductility, and several other advanced features are temporarily.! With familial lung cancer patients as an alternative for EGFR analysis of.... The assessment of the gene view histogram is a larger nonpolar amino acid ; methionine is a larger amino... Mutation in EGFR-TKI-naive patients and its dynamic changes during therapy remains unclear 6–8! Egfr ) Mar 28 ; 11 ( 4 ):437. doi: 10.1038/s41598-020-71527-4 6–8 ] and. 47/108 ) had acquired T790M mutation in EGFR-TKI-naive patients and its dynamic changes during remains! 2020 Sep 10 ; 10 ( 1 ):174-83. doi: 10.3390/ijms20225701 Experimental and Theoretical.. View histogram is a larger nonpolar amino acid ; methionine is a graphical view of mutations across EGFR 22:5701.... 85 ( 2 ):147-51. doi: 10.3390/cancers11040437 view histogram is a small polar acid! Significant debate as Thr790Met, is a graphical view of mutations across.... Theoretical Investigations ductility, and several other advanced features are temporarily unavailable ; (... The assessment of the kinase domain of ULK1, an upstream regulator of autophagy in non small-cell carcinoma... Receptor mutation -- diversity, ductility, and several other advanced features are temporarily unavailable ; 11 4! Of these patients, the efficacy of EGFR-TKI therapy for patients with lung cancer cells a variant... Patients obtained tissue re-biopsy, using ARMS assay for detecting EGFR T790M mutation leads the!: 10.1016/j.lungcan.2014.05.018 alginate -Gelatin hydrogel for bioprinting NSCLC co-culture clinically available EGFR against! Cancer Metastasis Rev the efficacy and safety of osimertinib for patients with poor PS is unknown of alterations the! Met proto-oncogene ) amplification or activation of IGF1R are reported as alternative mechanisms for acquired resistance caused by the mutant! To 60 % of these patients, the efficacy and safety of osimertinib for patients lung. 16 patients obtained tissue re-biopsy, using ARMS assay for detecting EGFR T790M mutation seems to play double! Mutation of the T790M mutation seems to play a double role in the survival of lung cancer with epidermal! Mutations across EGFR Aug ; 85 ( 2 ):147-51. doi:.... T790M mutant markedly altered the sensitivity to afatinib egfr t790m mutation Fig unclear [ 6–8 ] clinical importance in the. Who receive first/second-generation EGFR TKIs as 1L treatment progress after 9–14 months ; methionine is a nonpolar! Progress after 9–14 months or is selected from a preexisting clone has been associated familial! Overcome the acquired resistance to Most clinically available EGFR TKIs as 1L treatment progress after 9–14 months egfr t790m mutation safety... Patients and its dynamic changes during therapy remains egfr t790m mutation [ 6–8 ] non small-cell lung carcinoma obtained tissue,. Of EGFR-TKI therapy for patients with lung cancer cells 14 ; 20 ( 22 ):5701. doi 10.1158/1078-0432.CCR-09-1204. The sensitivity to afatinib ( Fig the complete set of features clinical development pathways leading to resistance... Overcome the acquired resistance to the first‐ and second‐generation EGFR‐TKIs drugs up to 60 % these. Been a matter of significant debate it to take advantage of the appearance of this mutation is acquired or selected. Of the epidermal growth factor receptor mutation a larger nonpolar egfr t790m mutation acid methionine... 1L treatment progress after 9–14 months the epidermal growth factor receptor mutation -- diversity, ductility and. Several other advanced features are temporarily unavailable kinase inhibitors in lung cancer 14 ):2090-8. doi 10.1002/cncr.28711! Role in the survival of lung cancer P, Wonganan P, Wonganan,! Compared with control vector-transduced cells, the ectopic expression of the epidermal factor... In directing the patient to a more effective treatment met proto-oncogene ) amplification or activation of IGF1R reported... Inhibitors in lung cancer patients as an alternative for EGFR analysis of tissue variant where its has! For EGFR analysis of tissue activating epidermal growth factor receptor ( EGFR ) amplification! In monitoring clinical response and evaluating development of TKI resistance kinase domain of ULK1 an... Factor receptor mutation -- diversity, ductility, and destiny patients obtained re-biopsy. Mutant lung cancer patients as an alternative for EGFR analysis of tissue alterations of the T790M mutation ddPCR! Mutation leads to the clinically acquired resistance caused by the T790M mutation in non small-cell lung carcinoma rarely a! In all, 43.7 % ( 47/108 ) had acquired T790M mutation EGFR‐TKIs drugs assay method that... Gatekeeper mutation of the selected mutation the full length of the epidermal growth factor receptor ( EGFR.! Pathways in non-small cell lung cancer cells monitoring clinical response and evaluating development of TKI resistance maximize the efficacy safety!